X
<
1
SuperValu Cruises past Analyst Expectations, Still Sinks

SuperValu (SVU) reported adjusted EPS of $0.46, beating the consensus by $0.10. Total sales from continuing operations stood at $3.8 billion—35% higher YoY.

kmis-adjusted-eps-vs-estimates-2-1
Kinder Morgan’s 3Q17 Results Met Analysts' Expectations

Kinder Morgan reported its 3Q17 results on October 18, 2017. It reported an adjusted EPS of $0.15, which was in-line with analysts’ consensus estimates.

Asian
Pre-Market Report: Global Markets Are Stable on October 20

On October 20, the Shanghai Composite Index closed at 3,378.65 after rising 0.25%. The SPDR S&P China ETF (GXC) fell 1.7% on October 19, 2017.

sP-500-1
Highs and Lows: Wall Street's Performance on October 19

After rising for five consecutive trading weeks, the S&P 500 started this week on a stronger note. It rose in the first three trading days of the week.

RECENT Healthcare RESEARCH

Chart-01-EPS-2-1
What Drives AstraZeneca’s Valuation after Its 2Q17 Earnings?

AstraZeneca’s (AZN) stock value has fallen ~11.9% over the last 12 months. Wall Street analysts estimate that the stock has the potential to return ~16.6% over the next 12 months.

recommendations
Boston Scientific: Its Plan to Accelerate and Sustain Growth

Wall Street analysts’ lowest one-year target price for Boston Scientific (BSX) stock is $24, representing a -11.4% maximum downside risk potential for the next year.

Graph-11-3-1
Ligand Pharmaceuticals’ Key Long-Term Growth Drivers

Royalties paid to Ligand Pharmaceuticals (LGND) based on the sales of Amgen’s (AMGN) Kyprolis are a major revenue driver for the company. In 2Q17, LGND earned royalties of ~$222 million on Kyprolis’ sales.

Chart-01-Rev-EPS-5-1
Valuation Drivers for Eli Lilly & Co. after Its 2Q17 Earnings

Eli Lilly (LLY) surpassed Wall Street estimates in 2Q17, reporting earnings per share of $1.11 on revenues of ~$5.8 billion. Analysts estimated that the company would report EPS of $1.05 on revenues of $5.6 billion.

sage
Product Recalls: Why Stryker Revised Its Fiscal 2Q17 Guidance

On August 23, Stryker (SYK) announced a voluntary product recall of specific lots of oral care products that form part of the company’s Sage business unit.

Chart-01-Rev-EPS-6-1
What Could Drive GlaxoSmithKline's Valuation after 2Q17?

As of August 30, 2017, GlaxoSmithKline is trading at a forward PE multiple of 13.3x, which is slightly lower than the industry average of 15.5x.

Analysts-Rating-1
How Vertex Pharmaceuticals Is Positioned after 2Q17

Around 80% of the analysts tracking Vertex Pharmaceuticals in August 2017 gave the stock some form of a “buy” rating.

REVENUE-ESTIMATES-3-1
How Zimmer Biomet's Transition Looks for 2017

Zimmer Biomet registered net sales of $1.95 billion, exceeding the analysts’ estimate, and saw year-over-year sales growth of around 1.1%.

Analysts-reco-1
Key Updates from United Therapeutics

In April 2017, United Therapeutics (UTHR) and 3D Systems (DDD) declared their plans to develop solid organ scaffolds for human transplants.

highlights
Medtronic’s Outlook for the Rest of Fiscal 2018

On August 22, Medtronic (MDT) recorded $7.4 billion in revenues for fiscal 1Q18, falling short of Wall Street’s estimate of $7.5 billion. In this series, we’ll examine MDT’s outlook for fiscal 2Q18 and fiscal 2018.

Chart-01-Rev-EPS-3-1
What's Likely Driving Novartis’s Valuation after 2Q17?

Novartis missed the analysts’ estimate for 2Q17 revenues, reporting $12.24 billion and falling short of $12.27 billion, but surpassed the estimate for EPS.

Graph-1-7-1
What Investors Need to Know about Ligand Pharmaceuticals in 2017

In 2Q17, Ligand Pharmaceuticals (LGND) reported revenues of ~$28.0 million, representing year-over-year growth of ~43.4%. LGND received ~$14.2 million in royalties, a year-over-year rise of 45.7%.

Analyst-recommendations-1
Regeneron Pharmaceuticals: Analysis after Solid 2Q17 Growth

Twenty-five analysts were analyzing Regeneron Pharmaceuticals in August 2017. Seven of them recommended a “strong buy,” and five recommended a “buy.”

Chart-01-Rev-EPS-2-1
What's Driving Bristol-Myers Squibb’s Valuation after 2Q17?

Bristol-Myers Squibb (BMY) met Wall Street analysts’ estimate for EPS at $0.74. It also surpassed the estimates for revenues.

Chart 01
What's Driving Johnson & Johnson's Post-2Q17 Valuation

Headquartered in New Jersey, Johnson & Johnson (JNJ) is one of the largest pharmaceutical companies, with its products sold in over 200 countries worldwide. This series will look at how it has performed since its 2Q17 earnings announcement.

highlights
Beckton Dickinson: Can Its 3Q17 Strong Results Continue?

Becton Dickinson (BDX) reported its 3Q17 earnings on August 3, 2017. The adjusted diluted EPS (earnings per share) came in at $2.46.

eps
Medtronic: A Post-1Q18 Checkup

Medtronic (MDT) reported its fiscal 1Q18 earnings on August 22, 2017. In this series, we’ll look at its stock performance since then.

Analysts-Reco-4-1
An Update on Merck after 2Q17: Keytruda, Januvia, and Janument

Of the 21 analysts tracking Merck in August 2017, three analysts recommended a “strong buy,” and ten analysts recommended a “buy.” Seven analysts recommended a “hold,” and one analyst recommended a “strong sell.”

Chart-01-2-1
What's Driving Ionis Pharmaceuticals’ Valuation?

Ionis Pharmaceuticals (IONS) has been one of the leading pharmaceutical companies in the RNA-targeted therapeutic space for over 26 years.

Graph-10-1
What to Expect from Jazz Pharmaceuticals’ Oncology Portfolio

Erwinaze saw net sales worth $49 million in 2Q17, almost flat compared to the drug’s revenues of $50 million in 2Q16.

X

Please select a profession that best describes you: